Nanotechnologies to use zoledronic acid as a potent antitumoral agent

G. Salzano, M. Marra, C. Leonetti, M. Porru, S. Zappavigna, A. Abbruzzese, M. I. La Rotonda, M. Caraglia, G. De Rosa

Research output: Contribution to journalArticle


Zoledronic acid, a new highly potent third generation aminobisphosphonate, is the drug currently used to prevent bone resorption in patients with bone metastases. Moreover, ZOL is a potent inducer of apoptosis in several cancer cell types, suggesting a direct anti-cancer activity that may affect a broad range of tumors. However, the rapid elimination from plasma, along with the rapid uptake and accumulation within bone, hampers the direct anti-cancer activity of ZOL in vivo. On the other hand, long circulating nanocarriers offer the opportunity to change the pharmacokinetics of encapsulated drugs, targeting tissues with an increased permeability of the vessels (e.g. tumors). In this study, we proposed two different strategies in order to avoid ZOL accumulation in bone and address the drug toward tumors. In particular, we designed and developed long circulating liposomes and self-assembly PEGylated nanoparticles for the delivery of ZOL into solid tumors.

Original languageEnglish
Pages (from-to)283-284
Number of pages2
JournalJournal of Drug Delivery Science and Technology
Issue number3
Publication statusPublished - May 2011


  • Self-assembly nanoparticles
  • Stealth liposomes
  • Zoledronic acid

ASJC Scopus subject areas

  • Pharmaceutical Science

Fingerprint Dive into the research topics of 'Nanotechnologies to use zoledronic acid as a potent antitumoral agent'. Together they form a unique fingerprint.

Cite this